Market research
ELOX Eloxx Pharmaceuticals, Inc.
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 66M
- P/E ratio
- 5.76
- Analyst target
- 40.3333
- Dividend yield
- Not available
- Beta
- -160692.25
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US29014R3012
- Market cap
- 66M
- P/E ratio
- 5.76
- Analyst target
- 40.3333
- Dividend yield
- Not available
- Beta
- -160692.25
About
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ELOX discussion.
5 years, 4 months ago
Eloxx Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 42.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Eloxx Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 197.2% to $-35M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.8% to $-5M since the same quarter in the previous year.
Based on the above factors, Eloxx Pharmaceuticals, Inc gets an overall score of 2/5.